IBA Lifesciences Transformed by Cube Biotech Acquisition

Deal News | Jan 16, 2025 | Archimed SAS

ARCHIMED has finalized the acquisition of IBA Lifesciences GmbH by its portfolio company, Cube Biotech. This acquisition is transformative for Cube Biotech, enhancing its capabilities and market position in protein purification technologies. IBA Lifesciences, headquartered in Germany, specializes in life science tools that include reagents for protein purification based on proprietary Strep-Tag affinity technology. This deal aims to integrate IBA's offerings with Cube's expertise to better serve the biotechnology sector. Cube Biotech, also based in Germany, is known for solutions in protein purification and stabilization. This acquisition is part of Cube Biotech's strategic initiative to accelerate innovation, expand its market reach, and boost profitability. The collaboration is expected to enhance service offerings in protein isolation and purification technologies, supporting further advancements in life sciences research.

Sectors

  • Biotechnology
  • Private Equity

Geography

  • Germany – Both IBA Lifesciences GmbH and Cube Biotech are headquartered in Germany, making it the primary geographical focus of the article.

Industry

  • Biotechnology – The article is primarily about Cube Biotech and IBA Lifesciences, which are both involved in biotechnology-related products and services, particularly protein purification and stabilization.
  • Private Equity – The article involves ARCHIMED, a private equity firm that orchestrated the acquisition through its portfolio company, Cube Biotech.

Financials

    Participants

    NameRoleTypeDescription
    IBA Lifesciences GmbHTarget CompanyCompanyA Germany-based company specializing in life science tools, particularly reagents for protein purification with proprietary technology.
    Cube BiotechAcquirerCompanyA company in Germany delivering solutions for protein purification and a portfolio company of ARCHIMED since 2021.
    ARCHIMED SASPrivate Equity FirmCompanyThe private equity firm that facilitated the acquisition through its portfolio company, Cube Biotech.
    Didier DargentCEO of Cube BiotechPersonOversaw the acquisition strategy for Cube Biotech and provided commentary on its significance.
    Dr. Mike RotheCEO of IBA LifesciencesPersonSpoke on the benefits of combining technologies and talents from both IBA Lifesciences and Cube Biotech.